Zynex Total Long-Term Assets 2010-2024 | ZYXI
Zynex total long-term assets from 2010 to 2024. Total long-term assets can be defined as the sum of all assets classified as non-current
| Zynex Annual Total Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024 | $47 |
| 2023 | $49 |
| 2022 | $47 |
| 2021 | $51 |
| 2020 | $9 |
| 2019 | $6 |
| 2018 | $5 |
| 2017 | $1 |
| 2016 | $1 |
| 2015 | $1 |
| 2014 | $1 |
| 2013 | $4 |
| 2012 | $5 |
| 2011 | $4 |
| 2010 | $3 |
| 2009 | $3 |
| Zynex Quarterly Total Long-Term Assets (Millions of US $) |
|
|---|---|
| 2024-12-31 | $47 |
| 2024-09-30 | $48 |
| 2024-06-30 | $48 |
| 2024-03-31 | $48 |
| 2023-12-31 | $49 |
| 2023-09-30 | $49 |
| 2023-06-30 | $45 |
| 2023-03-31 | $46 |
| 2022-12-31 | $47 |
| 2022-09-30 | $48 |
| 2022-06-30 | $49 |
| 2022-03-31 | $50 |
| 2021-12-31 | $51 |
| 2021-09-30 | $21 |
| 2021-06-30 | $22 |
| 2021-03-31 | $9 |
| 2020-12-31 | $9 |
| 2020-09-30 | $7 |
| 2020-06-30 | $7 |
| 2020-03-31 | $8 |
| 2019-12-31 | $6 |
| 2019-09-30 | $6 |
| 2019-06-30 | $6 |
| 2019-03-31 | $5 |
| 2018-12-31 | $5 |
| 2018-09-30 | $1 |
| 2018-06-30 | $1 |
| 2018-03-31 | $1 |
| 2017-12-31 | $1 |
| 2017-09-30 | $0 |
| 2017-06-30 | $1 |
| 2017-03-31 | $1 |
| 2016-12-31 | $1 |
| 2016-09-30 | $1 |
| 2016-06-30 | $1 |
| 2016-03-31 | $1 |
| 2015-12-31 | $1 |
| 2015-09-30 | $1 |
| 2015-06-30 | $1 |
| 2015-03-31 | $1 |
| 2014-12-31 | $1 |
| 2014-09-30 | $2 |
| 2014-06-30 | $2 |
| 2014-03-31 | $3 |
| 2013-12-31 | $4 |
| 2013-09-30 | $4 |
| 2013-06-30 | $5 |
| 2013-03-31 | $4 |
| 2012-12-31 | $5 |
| 2012-09-30 | $5 |
| 2012-06-30 | $4 |
| 2012-03-31 | $4 |
| 2011-12-31 | $4 |
| 2011-09-30 | $4 |
| 2011-06-30 | $4 |
| 2011-03-31 | $3 |
| 2010-12-31 | $3 |
| 2010-09-30 | $3 |
| 2010-06-30 | $3 |
| 2010-03-31 | $3 |
| 2009-12-31 | $3 |
| 2009-09-30 | $2 |
| 2009-06-30 | $2 |
| 2009-03-31 | $2 |
| Sector | Industry | Market Cap | Revenue |
|---|---|---|---|
| Medical | MED PRODUCTS | $0.067B | $0.192B |
| Zynex, Inc. engineers, manufactures, markets, and sells medical devices for the electrotherapy, and stroke and spinal cord injury rehabilitation markets primarily in the United States. The company primarily offers electrotherapy products for pain relief and pain management; and NeuroMove for stroke and spinal cord injury rehabilitation. The company's product lines are fully developed, FDA-cleared, commercially sold, and have been developed to uphold the Company's mission of improving the quality of life for patients suffering from impaired mobility due to stroke, spinal cord injury, or debilitating and chronic pain. Zynex markets its products through commissioned and independent sales representatives, as well as directly to end users through advertisements and articles in relevant publications and on the Internet. The company is headquartered in Littleton, Colorado. | |||